Fanconi anemia pathway deficiency drives copy number variation in squamous cell carcinoma.

Fanconi anemia (FA), a model syndrome of genome instability, is caused by a deficiency in DNA interstrand crosslink (ICL) repair resulting in chromosome breakage[1][1]–[3][2]. The FA repair pathway comprises at least 22 FANC proteins including BRCA1 and BRCA2[4][3]–[6][4], and protects against carcinogenic endogenous and exogenous aldehydes[7][5]–[10][6]. Individuals with FA are hundreds to thousands-fold more likely to develop head and neck (HNSCC), esophageal and anogenital squamous cell carcinomas (SCCs) with a median onset age of 31 years[11][7]. The aggressive nature of these tumors and poor patient tolerance of platinum and radiation-based therapy have been associated with short survival in FA[11][7]–[16][8]. Molecular studies of SCCs from individuals with FA (FA SCCs) have been limited, and it is unclear how they relate to sporadic HNSCCs primarily driven by tobacco and alcohol exposure or human papillomavirus (HPV) infection[17][9]. Here, by sequencing FA SCCs, we demonstrate that the primary genomic signature of FA-deficiency is the presence of a high number of structural variants (SVs). SVs are enriched for small deletions, unbalanced translocations, and fold-back inversions that arise in the context of TP53 loss. The SV breakpoints preferentially localize to early replicating regions, common fragile sites, tandem repeats, and SINE elements. SVs are often connected forming complex rearrangements. Resultant genomic instability underlies elevated copy number alteration (CNA) rates of key HNSCC-associated genes, including PIK3CA, MYC, CSMD1, PTPRD, YAP1, MXD4, and EGFR. In contrast to sporadic HNSCC, we find no evidence of HPV infection in FA HNSCC, although positive cases were identified in gynecologic tumors. A murine allograft model of FA pathway-deficient SCC was enriched in SVs, exhibited dramatic tumor growth advantage, more rapid epithelial-to-mesenchymal transition (EMT), and enhanced autonomous inflammatory signaling when compared to an FA pathway-proficient model. In light of the protective role of the FA pathway against SV formation uncovered here, and recent findings of FA pathway insufficiency in the setting of increased formaldehyde load resulting in hematopoietic stem cell failure and carcinogenesis[18][10]–[20][11], we propose that high copy-number instability in sporadic HNSCC may result from functional overload of the FA pathway by endogenous and exogenous DNA crosslinking agents. Our work lays the foundation for improved FA patient treatment and demonstrates that FA SCC is a powerful model to study tumorigenesis resulting from DNA crosslinking damage. ### Competing Interest Statement Rocket Pharmaceuticals provided research funding and partial salary support to A.S. for an unrelated project. P.J.C. is a founder, director and consultant for Mu Genomics Ltd. B.S. is a co-inventor of intellectual property related to DCN1 small molecule inhibitors licensed by MSK to Cinsanso. He has rights to receive royalty income as a result of this arrangement. MSK has financial interests related to this intellectual property and Cinsanso as a result of this arrangement. [1]: #ref-1 [2]: #ref-3 [3]: #ref-4 [4]: #ref-6 [5]: #ref-7 [6]: #ref-10 [7]: #ref-11 [8]: #ref-16 [9]: #ref-17 [10]: #ref-18 [11]: #ref-20